<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04997447</url>
  </required_header>
  <id_info>
    <org_study_id>SKR:271901-36456</org_study_id>
    <nct_id>NCT04997447</nct_id>
  </id_info>
  <brief_title>Enforced Reduction in Physical Activity and Recovery in Older Adults</brief_title>
  <acronym>ENDURE</acronym>
  <official_title>Enforced Reduction in Physical Activity and Recovery in Older Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Jyvaskyla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Eastern Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Jyvaskyla</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Apparently healthy and well-functioning community dwelling 70-80 year-olds will be recruited&#xD;
      to the study. All subjects undergo pre-screening for suitability and a physicians&#xD;
      examination, as well as 7-day habitual daily steps are measured to ascertain baseline&#xD;
      physical activity. Half of the recruited subjects (n=40) will be randomized into the&#xD;
      intervention group and half (n=40) randomized into the control group. The intervention group&#xD;
      is then required to reduce their daily steps to &lt;2000 for a 2-week period. Thereafter, the&#xD;
      intervention group participates to a 4-week strength+endurance training rehabilitation&#xD;
      program and no longer has restricted daily step count. The control group continues their&#xD;
      normal habitual physical activity level throughout the 6-week study period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized Controlled Trial, with 2 parallel groups</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lean leg mass</measure>
    <time_frame>6 weeks</time_frame>
    <description>DXA-measured total lean mass of the legs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Whole-body fat mass</measure>
    <time_frame>6 weeks</time_frame>
    <description>DXA-measured total body fat mass</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum isometric leg extension force</measure>
    <time_frame>6 weeks</time_frame>
    <description>Maximum strength of legs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking economy</measure>
    <time_frame>6 weeks</time_frame>
    <description>Oxygen uptake while walking at 3 and 5 km.h-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Physical Performance Battery (SPPB)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Walking, balance and chair-rise tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>6 weeks</time_frame>
    <description>Systolic and diastolic blood pressure during rest (sitting)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOMA indices</measure>
    <time_frame>6 weeks</time_frame>
    <description>Blood glucose and insulin concentration based calculations related to insulin resistance and beta-cell function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White blood cell respiration</measure>
    <time_frame>6 weeks</time_frame>
    <description>Isolated white blood cell respiration as a marker for mitochondrial function</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Muscle Degeneration</condition>
  <condition>Body Weight Changes</condition>
  <condition>Walking, Difficulty</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two weeks of daily step reduction (limited to 2000 steps per day) followed by four weeks of supervised gym-based exercise rehabilitation (twice per week strength training and twice per week cycle endurance training)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Continued monitoring of habitual daily step count without structured intervention. Classic control.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Step-reduction/Exercise Rehab</intervention_name>
    <description>2-week limited daily steps (&lt;2000), and then 4 weeks of typical strength+endurance exercise for older adults</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. aged 70-80 years,&#xD;
&#xD;
          2. community-dwelling,&#xD;
&#xD;
          3. able to walk 500 m without assistance or use of walking aid and regularly walking&#xD;
             &gt;5000 steps per day,&#xD;
&#xD;
          4. MMSE &gt;24,&#xD;
&#xD;
          5. BMI 20-35 kg·m2 (i.e. not underweight or severely obese),&#xD;
&#xD;
          6. no serious cardiovascular or musculoskeletal disease,&#xD;
&#xD;
          7. no risk factors for deep-vein thrombosis (e.g. blood clotting disorder, obesity, bowel&#xD;
             diseases, personal or family history of DVT etc.),&#xD;
&#xD;
          8. non-smoker,&#xD;
&#xD;
          9. provision of informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Underlying diseases likely to limit lifespan and/or intervention safety.&#xD;
             Contraindication for physical exercise or physical tests identified during physician's&#xD;
             examination,&#xD;
&#xD;
          2. unwilling/unable to track daily step counts using accelerometer,&#xD;
&#xD;
          3. excessive and regular use of alcohol (more than 7 units per week for women and 14 for&#xD;
             men)&#xD;
&#xD;
          4. difficulty in communication due to severe vision or hearing problems&#xD;
&#xD;
          5. unwilling to provide consent or accept randomization into either study group&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon Walker, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Jyväskylä, Finland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Simon Walker, PhD</last_name>
    <phone>+358408054906</phone>
    <email>simon.walker@jyu.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ulla-Maria Sahinaho, MSc</last_name>
    <phone>+358505762204</phone>
    <email>ulla-maria.u-m.sahinaho@jyu.fi</email>
  </overall_contact_backup>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 1, 2021</study_first_submitted>
  <study_first_submitted_qc>August 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2021</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Body Weight Changes</mesh_term>
    <mesh_term>Mobility Limitation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

